New buy­ers lin­ing up bids for No­var­tis' gi­ant gener­ics arm

With the fate of No­var­tis’ gener­ics unit up in the air, more po­ten­tial buy­ers are re­port­ed­ly lin­ing up for what could be one of the largest M&A deals the in­dus­try has seen in the last year or so.

Black­stone and the Car­lyle Group are con­sid­er­ing a joint of­fer for San­doz that could val­ue that unit at up to $25 bil­lion, Bloomberg and the Fi­nan­cial Times re­port­ed on Tues­day. Some­one with knowl­edge of the mat­ter has con­firmed to End­points News that Car­lyle is in talks with Black­stone re­gard­ing a po­ten­tial of­fer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN